Omicron Research Ltd has a robust customer base in the UK and Irish pharmaceutical industry as a leading supplier of dissolution, chromatography and spectroscopy instruments. The company began life as the sales branch of a manufacturer of dissolution systems for oral solid drugs. The addition of ISAB to its roster will enable it to expand into R&D labs for inhaled drugs.

As well as ISAB's leading dissolution technology DissolvIt®, Omicron Research will represent and actively promote ISAB's entire product and service portfolio - from its flagship aerosol generator PreciseInhale®, with in vivo modules for exceptionally precise exposures, to its air-liquid interface instrument XposeALI® for permeability tests of biologics, to its contract research services under Inhalation Research Services.

Omicron Research Ltd's General Manager Sam Stringer: "We are excited to be able to bring ISAB's innovative products and research services to our marketplace to facilitate the growth of both our companies. The addition of ISAB to our portfolio allows us to strengthen our position in current industry sectors whilst providing the opportunity to expand into others."

ISAB CEO Manoush Masarrat: "The UK and Ireland are both vital markets for us. We are confident that this new agreement will help increase our customer base and sales in these markets."